- About Journal
- Literature browse
- For Authors
- For Reviewers
- News and Events
- Personal Center
- Logout
FOLLOWUS
- About Journal
- Literature browse
- For Authors
- For Reviewers
- News and Events
- Share with wechat friends or circle of friends
UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases- Affiliations：
1.Central Laboratory of the Fifth Affiliated Hospital of Harbin Medical University, Daqing 163711, Heilongjian Province, China
2. Clinical Laboratory of the Fifth Affiliated Hospital of Harbin Medical University, Daqing 163316, Heilongjian Province, China
- Author bio：
E-mail: yudejun100@126.com
- Funds：
DOI：10.24920/004340
CLC：Published：30 September 2024，
Published Online：20 May 2024，
Received：16 January 2024，
Accepted：2024-04-18
- Accepted：
Scan QR Code
.UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases[J]. 中国医学科学杂志（英文）,2024,39(03):171-181.
CUI YUE, WANG HONG-ZHI, SONG YE, et al.
UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases. [J]. 中国医学科学杂志（英文）;chinese medical sciences journal, 2024, 39(3): 171-181..UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases[J]. 中国医学科学杂志（英文）,2024,39(03):171-181. DOI： 10.24920/004340.
CUI YUE, WANG HONG-ZHI, SONG YE, et al.
UBE2C as an Immune-Related Biomarker for Breast Cancer: A Study Based on Multiple Databases. [J]. 中国医学科学杂志（英文）;chinese medical sciences journal, 2024, 39(3): 171-181. DOI： 10.24920/004340.
摘要
目的
2
利用多种基因表达数据库和公共生物信息学平台，分析出与乳腺癌预后和免疫相关的关键基因，并对关键基因在乳腺癌中的预后价值和免疫作用情况进行验证和探讨。
方法
2
从Gene Expression Omnibus（GEO）数据库下载乳腺癌基因芯片表达数据集，分析获得差异表达基因（differentially expressed genes，DEGs）。通过构建和可视化DEGs-蛋白相互作用网络获得枢纽基因，利用R语言、STRING和Cytoscape等工具在枢纽基因中确定关键基因，利用外部数据集和The Cancer Genome Atlas（TCGA）验证关键基因差异表达情况，利用定量实时聚合酶链式反应（quantitative real-time polymerase chain reaction，qRT-PCR）验证关键基因在37个乳腺癌组织和相对应的癌旁组织中的差异表达情况，使用R语言、TIMER和Gene Set Enrichment Analysis（GSEA）等生物信息学工具和平台研究关键基因在乳腺癌中的预后价值和免疫学相关性。
结果
2
率先从302个差异基因中获取了10个枢纽基因，并通过生存分析筛选出关键基因UBE2C。GEO独立数据集、TCGA和qRT-PCR均证实UBE2C在乳腺癌组织中差异上调。预后分析显示UBE2C是一个独立的预后因素。UBE2C高表达降低乳腺癌组织中B细胞、CD4+ T细胞、CD8+ T细胞、巨噬细胞和髓系树突状细胞免疫浸润水平。UBE2C在乳腺癌中的表达与免疫检查点基因PDCD1、CD274和CTLA4的表达显著相关。UBE2C的表达与肿瘤突变负荷水平和微卫星不稳定性水平呈显著正相关。GSEA分析显示，在786个免疫相关基因集中UBE2C表达显著富集。
结论
2
UBE2C在乳腺癌组织中的表达与乳腺癌免疫微环境密切相关，其表达情况对预测乳腺癌患者的生存、预后和免疫治疗效果具有一定价值。UBE2C是乳腺癌的一种潜在的免疫相关的预后生物标志物。
Abstract
Objective
2
To screen the target genes that are associated with survival of breast cancer (BRCA) and explore their prognostic values and immune correlations with BRCA using multiple databases..
Methods
2
The microarray expression datasets of BRCA were downloaded from the Gene Expresssion Omnibus database (GEO) and analyzed to obtain differentially expressed genes (DEGs). Hub genes were obtained by constructing and visualizing the protein-protein interaction network of DEGs. The key gene was determined using R language
STRING
and Cytoscape
and the differential expression of the key gene was verified using external datasets The Cancer Genome Atlas (TCGA) and quantitative real-time PCR (qRT-PCR) for BRCA tissues of 37 patients. The prognostic value and immunological correlation of
UBE2C
in BRCA were explored using R language
TIMER
and Gene Set Enrichment Analysis (GSEA).
Results
2
Of 10 hub genes seleceed from 302 DEGS
UBE2C
was identified as the gene associated with BRCA survival. The expression of
UBE2C
was differentially upregulated in BRCA
as verified by TCGA and qRT-PCR. Prognostic analysis revealed that
UBE2C
served as an independent prognostic factor. High expression of
UBE2C
was associated with decreased immune infiltration levels of B cells
CD4+ T cells
CD8+ T cells
macrophages
and myeloid dendritic cells in BRCA tissue. The expression of
UBE2C
in BRCA showed a significant correlation with immune checkpoints genes
PDCD1
CD274
and
CTLA4
expressions. There was a positive correlation between the expression of
UBE2C
and the tumor mutational burden and microsatellite instability. GSEA demonstrated that
UBE2C
expression significantly enriched 786 immune-related gene sets.
Conclusions
2
UBE2C
expression in BRCA tissues is closely related to the BRCA immune microenvironment and showes predictive values on the survivals
and prognosis of BRCA patients and the effecacy of immunotherapy.
UBE2C
may be an potential immune-related prognostic biomarker for BRCA.
关键词
UBE2C乳腺癌预后生物标志物免疫生存分析生物信息学
Keywords
UBE2Cbreast Cancerprognostic biomarkerimmunebioinformatics analysessurvival
references
Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol2020; 84: 106535. doi: 10.1016/j.intimp.2020.106535http://dx.doi.org/10.1016/j.intimp.2020.106535.
Bray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2024; 74 (3): 229-63. doi: 10.3322/caac.21834http://dx.doi.org/10.3322/caac.21834.
Zheng RS, Chen R, Han BF, et al. [Cancer incidence and mortality in China, 2022]. Zhong Hua Zhong Liu Za Zhi2024; 46 (3): 221-31. doi: 10.3760/cma.j.cn112152-20240119-00035. (Chinesehttp://dx.doi.org/10.3760/cma.j.cn112152-20240119-00035.(Chinese)
Li Z, Chen Z, Hu G, et al. Roles of circular RNA in breast cancer: present and future. Am J Transl Res2019; 11 (7): 3945-54.
Liang G, Ling Y, Mehrpour M, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol Cancer2020; 19 (1): 65. doi: 10.1186/s12943-020-01152-2http://dx.doi.org/10.1186/s12943-020-01152-2.
Huang GZ, Chen ZQ, Wu J, et al. Pan-cancer analyses of the tumor microenvironment reveal that ubiquitin-conjugating enzyme E2C might be a potential immunotherapy target. J Immunol Res 2021; 9250207. doi: 10.1155/2021/9250207http://dx.doi.org/10.1155/2021/9250207.
Mo CH, Gao L, Zhu XF, et al. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int2017; 17: 83. doi: 10.1186/s12935-017-0455-1http://dx.doi.org/10.1186/s12935-017-0455-1.
Wang Y, Wang J, Tang Q, et al. Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis. PLoS One2021; 16 (2): e0247827. doi: 10.1371/journal.pone.0247827http://dx.doi.org/10.1371/journal.pone.0247827.
Li R, Pang XF, Huang ZG, et al. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC Cancer2021; 21 (1): 996. doi: 10.1186/s12885-021-08634-6http://dx.doi.org/10.1186/s12885-021-08634-6.
Chiang AJ, Li CJ. UBE2C drives human cervical cancer progression and is positively modulated by mTOR. Biomolecules2020; 11 (1): 37. doi: 10.3390/biom11010037http://dx.doi.org/10.3390/biom11010037.
Li J, Zhi X, Shen X, et al. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1. Biochem Bioph Res Co2020; 523 (2): 434-40. doi: 10.1016/j.bbrc.2019.12.058http://dx.doi.org/10.1016/j.bbrc.2019.12.058.
Liu Y, Huang F, Chen H, et al. Expression of UBE2C in lung adenocarcinoma based on database analysis and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban2020; 45 (9): 1044-52. doi: 10.11817/j.issn.1672-7347.2020.190189. (Article in English, Chinesehttp://dx.doi.org/10.11817/j.issn.1672-7347.2020.190189.(ArticleinEnglish,Chinese)
Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.Tumour Biol2012; 33 (3): 723-30. doi: 10.1007/s13277-011-0291-1http://dx.doi.org/10.1007/s13277-011-0291-1.
Chen DT, Nasir A, Culhane A, et al. Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat2010; 119 (2): 335-46. doi: 10.1007/s10549-009-0344-yhttp://dx.doi.org/10.1007/s10549-009-0344-y.
Liu RZ, Graham K, Glubrecht DD, et al. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol2011; 178 (3): 997-1008. doi: 10.1016/j.ajpath.2010.11.075http://dx.doi.org/10.1016/j.ajpath.2010.11.075.
Sinn BV, Fu C, Lau R, et al. SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer2019; 5 : 16. doi: 10.1038/s41523-019-0111-0http://dx.doi.org/10.1038/s41523-019-0111-0.
Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res2002; 30 (1): 207-10. doi: 10.1093/nar/30.1.207http://dx.doi.org/10.1093/nar/30.1.207.
Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 2013; 41 (Database issue): D991-5. doi: 10.1093/nar/gks1193http://dx.doi.org/10.1093/nar/gks1193.
Zhang X, Zhang W, Jiang Y, et al. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data. J Cell Biochem2019; 120 (10): 17898-911. doi: 10.1002/jcb.29058http://dx.doi.org/10.1002/jcb.29058.
Sun J, Huang J, Lan J, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int2019; 19: 264. doi: 10.1186/s12935-019-0986-8http://dx.doi.org/10.1186/s12935-019-0986-8.
Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics2012; 16 (5): 284-7. doi: 10.1089/omi.2011.0118http://dx.doi.org/10.1089/omi.2011.0118.
Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet2003; 34 (3): 267-73. doi: 10.1038/ng1180http://dx.doi.org/10.1038/ng1180.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A2005; 102 (43): 15545-50. doi: 10.1073/pnas.0506580102http://dx.doi.org/10.1073/pnas.0506580102.
Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res2021; 49 (D1): D605-12. doi: 10.1093/nar/gkaa1074http://dx.doi.org/10.1093/nar/gkaa1074.
von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res2003; 31 (1): 258-61. doi: 10.1093/nar/gkg034http://dx.doi.org/10.1093/nar/gkg034.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res2003; 13 (11): 2498-504. doi: 10.1101/gr.1239303http://dx.doi.org/10.1101/gr.1239303.
Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Sys Bio 2014; 8Suppl 4 (Suppl 4): S11. doi: 10.1186/1752-0509-8-s4-s11http://dx.doi.org/10.1186/1752-0509-8-s4-s11.
Gruosso T, Mieulet V, Cardon M, et al. Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med2016; 8 (5): 527-49. doi: 10.15252/emmm.201505891http://dx.doi.org/10.15252/emmm.201505891.
Liu Z, Mi M, Li X, et al. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer. J Cell Mol Med2020; 24 (21): 12444-56. doi: 10.1111/jcmm.15762http://dx.doi.org/10.1111/jcmm.15762.
Xiong Y, Yuan L, Xiong J, et al. An outcome model for human bladder cancer: A comprehensive study based on weighted gene co-expression network analysis. J Cell Mol Med2020; 24 (3): 2342-55. doi: 10.1111/jcmm.14918http://dx.doi.org/10.1111/jcmm.14918.
Jeong SH, Kim RB, Park SY, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol2020; 46 (1): 195-201. doi: 10.1016/j.ejso.2019.09.143http://dx.doi.org/10.1016/j.ejso.2019.09.143.
Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol2016; 17 (1): 218. doi: 10.1186/s13059-016-1070-5http://dx.doi.org/10.1186/s13059-016-1070-5.
Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics (Oxford, England)2019; 35 (14): i436-45. doi: 10.1093/bioinformatics/btz363http://dx.doi.org/10.1093/bioinformatics/btz363.
Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife2017; 6: e26476. doi: 10.7554/eLife.26476http://dx.doi.org/10.7554/eLife.26476.
Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res2020; 48 (W1): W509-14. doi: 10.1093/nar/gkaa407http://dx.doi.org/10.1093/nar/gkaa407.
Dastsooz H, Cereda M. A comprehensive bioinformatics analysis of UBE2C in cancers. Int J Mol Sci2019; 20 (9). doi: 10.3390/ijms20092228http://dx.doi.org/10.3390/ijms20092228.
Jiang X, Yuan Y, Tang L, et al. Comprehensive pan-cancer analysis of the prognostic and immunological roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis. Front Cell Dev Biol2021; 9 : 765772. doi: 10.3389/fcell.2021.765772http://dx.doi.org/10.3389/fcell.2021.765772.
Lu ZN, Song J, Sun TH, et al. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway. Chin Med J (Engl)2021; 134 (20): 2465-74. doi: 10.1097/cm9.0000000000001708http://dx.doi.org/10.1097/cm9.0000000000001708.
Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell Death Discov2022; 8 (1): 130. doi: 10.1038/s41420-022-00935-4http://dx.doi.org/10.1038/s41420-022-00935-4.
Huang R, Liu J, Li H, et al. Identification of hub genes and their correlation with immune infiltration cells in hepatocellular carcinoma based on GEO and TCGA databases. Front Genet2021; 12: 647353. doi: 10.3389/fgene.2021.647353http://dx.doi.org/10.3389/fgene.2021.647353.
Publicity Resources
Related Articles
Related Author
Related Institution
- © 2024 Chinese Academy of Medical Sciences 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.